<?php
$GLOBALS['title'] = "Newsroom - CancerVax";
$GLOBALS['desc'] = "";
$videos = include "data/podcast-data.php";
$GLOBALS['keywords'] = "";
include('header.php'); ?>

<section class="marketbanner" style="background-image: url(./assets/img/new-bg.jpg);">
    <div class="container">
        <h1>Newsroom</h1>
    </div>
</section>

<section class="news">
    <div class="container">
        <h4>Press Releases</h4>
        <div class="row">
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-precision-therapy-successfully-avoids-healthy-liver-cells.php"></a>
                    <span>October 14, 2025 </span>
                    <h3>CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that recent in-vitro studies have confirmed that the Company’s technology could significantly reduce liver toxicity, a major problem with other cancer drugs</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="legendary-scientist-and-biotech-veteran-joins-cancervax-as-strategic-advisor.php"></a>
                    <span>September 3, 2025 </span>
                    <h3>Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that Gordon Ringold, PhD, has joined the Company and will serve as Strategic Advisor</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-achieves-major-milestones-and-files-foundational-patent-application.php"></a>
                    <span>August 26, 2025 </span>
                    <h3>CancerVax Achieves Major Milestones and Files Foundational Patent Application</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that it recently filed a foundational PCT patent application to protect its novel innovations</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="scientists-discuss-the-recent-cancervax-breakthrough.php"></a>
                    <span>August 19, 2025 </span>
                    <h3>Scientists Discuss the Recent CancerVax Breakthrough</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced the release of a video presentation featuring its scientific team discussing the recent breakthrough</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-successfully-disguises-cancer-cells-and-tricks-immune-cells-into-attacking-them.php"></a>
                    <span>August 5, 2025 </span>
                    <h3>CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it has proven a major foundational hypothesis</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-nanoparticle-successfully-targets-cancer-cells-while-sparing-non-cancerous-cells.php"></a>
                    <span>June 19, 2025 </span>
                    <h3>CancerVax Nanoparticle Successfully Targets Cancer Cells While Sparing Non-cancerous Cells</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that its ligand conjugated lipid nanoparticle (“LNP”) successfully targeted cancer cells and avoided non-cancerous cells</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-targets-liver-cancers-to-further-showcase-flexibility-of-its-universal-platform.php"></a>
                    <span>June 9, 2025 </span>
                    <h3>CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancerVax-achieves-major-milestone-with-successful-creation-of-cell-targeting-nanoparticle.php"></a>
                    <span>June 5, 2025 </span>
                    <h3>CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform designed to use the body’s immune system to treat cancer, today announced the successful creation of its nanoparticle that can target specific cells that are potentially cancerous</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-scientists-featured-on-cytiva-discovery-matters-podcast-discussing-universal-cancer-vaccine-platform.php"></a>
                    <span>June 3, 2025 </span>
                    <h3>CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, today announced that two of its lead scientists, Dr. George Katibah and Dr. Adam Grant, were recently featured on Cytiva’s influential podcast series, Discovery Matters. The episode highlights CancerVax’s revolutionary approach to immunotherapy and its mission to create a therapy that can universally target and destroy cancer cells</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="top-biotech-exec-joins-cancervax-as-chief-scientific-advisor.php"></a>
                    <span>February 27, 2025 </span>
                    <h3>Top Biotech Exec Joins CancerVax as Chief Scientific Advisor</h3>
                    <p>CancerVax, Inc., the developer of a revolutionary universal cancer treatment platform that will use the body’s immune system to treat cancer, announced today that Sumant Ramachandra, MD, PhD, MBA and founder of SR Global Health, LLC, a healthcare advisory firm, will serve as the Company’s new Chief Scientific Advisor</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-announces-successful-tests-of-its-smart-mrna-technology.php"></a>
                    <span>February 25, 2025</span>
                    <h3>CancerVax Announces Successful Tests of its Smart mRNA Technology</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to treat cancer, today announced the successful functional validation of its innovative Smart mRNA (messenger RNA) technology in lab tests</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-targets-hard-to-treat-pancreatic-cancer.php"></a>
                    <span>December 11, 2024  </span>
                    <h3>CancerVax Targets Hard to Treat Pancreatic Cancer</h3>
                    <p>CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to treat cancer, announced today that the Company has selected Pancreatic Ductal Adenocarcinoma (PDAC) as one of its first targets for preclinical development</p>
                </div>
        </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-lands-top-cancer-expert-2.php"></a>
                    <span> November 19, 2024 </span>
                    <h3>CancerVax Lands Top Cancer Expert</h3>
                    <p> CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, announced today that Dr. George Katibah will serve as the company’s Chief Scientific Officer</p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-taps-flashpoint-therapeutics-nanotechnology-platform-to-drive-universal-cancer-treatment.php"></a>
                    <span> August 29, 2024</span>
                    <h3>Cancervax Taps Flashpoint Therapeutics’ Nanotechnology Platform to Drive Universal Cancer Treatment  </h3>
                    <p> Cancervax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to treat cancer, today announced that the Company has entered into a research agreement with Flashpoint Therapeutics to perform research on its newly patent-pending Universal Cancer Treatment platform </p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-files-new-patent-for-its-novel-universal-cancer-treatment-platform.php"></a>
                    <span> August 27, 2024</span>
                    <h3>Cancervax Files New Patent for Its Novel Universal Cancer Treatment Platform </h3>
                    <p> Cancervax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to treat cancer, today announced that the Company has recently filed a new patent application which includes a Smart mRNA Technology. mRNA, short for messenger RNA, is the underlying technology that made the COVID-19 vaccine so effective and inexpensive </p>
                </div>
            </div>
        <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-adds-key-members-to-its-research-team.php"></a>
                    <span> August 1, 2024</span>
                    <h3>Cancervax Adds Key Members to Its Research Team </h3>
                    <p> Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to treat cancer, today announced that the Company has added two key members to its cancer research team. Dr. Jonathan Lakey will serve as Chief Scientific Advisor and Dr. Adam Grant will serve as Principal Scientist </p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-successfully-uses-nobel-prize-chemistry-to-achieve-universal-cancer-vaccine-targeting-milestone.php"></a>
                    <span> May 21, 2024</span>
                    <h3>Cancervax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Treatment Targeting Milestone </h3>
                    <p> Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to treat cancer, today announced that its UCLA research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNP) using “click chemistry”, for targeting cancer cells </p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-announces-promising-new-drug-to-treat-a-deadly-children-cancer.php"></a>
                    <span> April 16, 2024 </span>
                    <h3>Cancervax Announces Promising New Drug to Treat a Deadly Children’s Cancer </h3>
                    <p> Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to treat cancer, today announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer </p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-launches-5-million-funding-round.php"></a>
                    <span> April 3, 2024 </span>
                    <h3>Cancervax Launches $5 Million Funding Round </h3>
                    <p> Cancervax, Inc., developer of a breakthrough Universal Cancer Treatment that will use the body’s immune system to treat cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million. Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments </p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-ceo-ryan-davies-discusses-cancer-drug-development-with-dr-ezra-cohen.php"></a>
                    <span>November 2, 2023 </span>
                    <h3>Cancervax CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen</h3>
                    <p> Cancervax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to treat cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="ucart-announcement.php"></a>
                    <span>September 12, 2023 </span>
                    <h3>Cancervax Expands Development Pipeline to Include a Universal CAR-T Cell Platform</h3>
                    <p> Cancervax, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to treat cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-ceo-ryan-davies-discussed-cancer-immunotherapy-with-ucla-physician-scientist.php"></a>
                    <span>August 24, 2023 </span>
                    <h3>Cancervax CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist</h3>
                    <p>Cancervax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to treat cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="world-renowned-biomedical-professor-jonathan-lakey-joins-cancervax-board-of-advisors.php"></a>
                    <span>July 25, 2023 </span>
                    <h3>World Renowned Biomedical Professor Jonathan Lakey Joins Cancervax Board of Advisors</h3>
                    <p>Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in cell and tissue transplantation for patients suffering from diabetes and cancer</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-ceo-ryan-davies-discusses-biotech-entrepreneurship-with-pyxis-oncology-ceo-dr-lara-sullivan.php"></a>
                    <span>July 10, 2023 </span>
                    <h3>Cancervax CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan</h3>
                    <p>The two industry leaders focus on navigating the biotech industry and immuno-oncology research</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-reports-significant-progress-on-universal-cancer-vaccine-development-at-ucla.php"></a>
                    <span>June 27, 2023</span>
                    <h3>Cancervax Reports Significant Progress on Universal Cancer Treatment Development at UCLA</h3>
                    <p>Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct </p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="biotech-executive-michael-dmith-discusses-the-fda-drug-development-process-with-cancervax-ceo-ryan-davies.php"></a>
                    <span>June 16, 2023</span>
                    <h3>Biotech Executive Michael Smith Discusses the FDA Drug Development Process with Cancervax CEO Ryan Davies </h3>
                    <p>Michael Smith comments on the growth of immunotherapy and sees the required FDA development phases as a benefit to small biotech firms such as Cancervax</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancerax-reports-positive-progress-on-kids-cancer-immunotherapy-treatment.php"></a>
                    <span>June 12, 2023</span>
                    <h3>Cancervax Reports Positive Progress on Kids Cancer Immunotherapy Treatment </h3>
                    <p>LEHI, Utah, June 12, 2023 (GLOBE NEWSWIRE) -- Cancervax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to treat cancer, today announced</p>
                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="biotech-entrepreneur-and-venture-capitalist-dinesh-patel-discusses-therapeutics-and-medical-devices-with-cancervax-ceo-ryan-davies.php"></a>
                    <span>May 17, 2023</span>
                    <h3>Biotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with Cancervax CEO Ryan Davies</h3>
                    <p>Lehi, UT – May 17, 2023 – Cancervax, developer of a breakthrough universal cancer treatment that will use the body’s immune system to treat cancer, today reported that the Company’s CEO, Ryan Davies</p>

                </div>
            </div>

            <div class="col-lg-6">
                <div class="news-item">
                    <a href="former-pfizer-legal-counsel-discusses-gene-therapy-with-cancervax-ceo-ryan-davies.php"></a>
                    <span>April 20, 2023</span>
                    <h3>Former Pfizer Legal Counsel Discusses Gene Therapy with Cancervax CEO Ryan Davies</h3>
                    <p>Stephen Diamond, Senior Vice President, General Counsel, and Secretary of Freeline, discussed his unique path from the legal and business worlds to gene therapy and next-generation therapeutics.</p>

                </div>

            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-ceo-ryan-davies-discusses-cancer-research-with-leading-pediatric-hematologic-oncologist.php"></a>
                    <span>April 12, 2023</span>
                    <h3>Cancervax CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist</h3>
                    <p>Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy</p>

                </div>

            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-lands-byron-elton.php"></a>
                    <span>April 3, 2023</span>
                    <h3>Cancervax Lands Byron Elton</h3>
                    <p>Experienced business executive to help establish the Company as a significant force in the field of cancer research</p>

                </div>

            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-ceo-ryan-davies-speaks-with-university-of-utah-chemistry-professor-about-the-future-of-fherapeutic-research.php"></a>
                    <span>March 24, 2023</span>
                    <h3>Cancervax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research</h3>
                    <p>Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with Cancervax CEO Ryan Davies to discuss the future of novel therapeutics and how the industry can encourage young scientists to enter the field.</p>

                </div>

            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="leading-diabetes-researcher-speaks-groundbreaking.php"></a>
                    <span>March 22, 2023</span>
                    <h3>Leading Diabetes Researcher Speaks on his Groundbreaking ‘Edmonton Protocol’ with Cancervax CEO Ryan Davies</h3>
                    <p>Dr. Jonathan Lakey, Professor in University of California – Irvine’s Surgery and Biomedical Engineering departments, spoke with Cancervax CEO Ryan Davies on his accomplishments in scientific research and their impact on the world</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-ceo-ryan-davies-sits-down-with-oncology-research-leader.php"></a>
                    <span>March 20, 2023</span>
                    <h3>Cancervax CEO Ryan Davies Sits Down with Oncology Research Leader</h3>
                    <p>Dr. David Bearss, an oncology researcher and biotech start-up founder, spoke with Cancervax CEO Ryan Davies on the future of oncology therapeutics</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-universal-cancer-vaccine-being-developed-by-UCLA.php"></a>
                    <span>March 17, 2023</span>
                    <h3>Cancervax Universal Cancer Treatment Being Developed by UCLA</h3>
                    <p>The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer treatment that will train the body to target and destroy cancer cells.</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-files-non-provisional-patent-for-universal-cancer-vaccine.php"></a>
                    <span>March 16, 2023</span>
                    <h3>Cancervax Files Non-Provisional Patent for Universal Cancer Treatment</h3>
                    <p>The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies to develop a breakthrough universal cancer treatment</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-announces-research-program-to-develop-its-second-immunotherapy-cancer-treatment.php"></a>
                    <span>August 31, 2022</span>
                    <h3>Cancervax Announces Research Program to Develop Its Second Immunotherapy Cancer Treatment</h3>
                    <p>The Company has entered into a Sponsored Research Agreement with UCLA to develop a new cancer immunotherapy universal cancer treatment.</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-files-provisional-patent-for-a-universal-cancer-vaccine.php"> </a>
                    <span>October 6, 2021</span>
                    <h3>Cancervax Files Provisional Patent for a Universal Cancer Treatment</h3>
                    <p>The Company plans to leverage cutting-edge CRISPR and mRNA technologies in its quest to develop a breakthrough universal cancer treatment.</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="biotech-executive-joins-cancervax.php"> </a>
                    <span>October 1, 2021</span>
                    <h3>Biotech Executive Joins Cancervax</h3>
                    <p>New CEO Ryan Davies will lead the Company’s development of its breakthrough immunotherapy treatment SANTA BARBARA, CA – October 1, 2021 – Cancervax, Inc.</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-announces-research-program.php"> </a>
                    <span>May 26, 2021</span>
                    <h3>Cancervax Announces Research Program</h3>
                    <p>The Company has entered into an agreement with UCLA to develop an immunotherapy breakthrough targeted at treating Ewing sarcoma, a rare but deadly soft tissue and bone cancer that primarily affects children and young adults.</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-closes-series-a-funding-round.php"> </a>
                    <span>March 30, 2021</span>
                    <h3>Cancervax Closes Series A Funding Round</h3>
                    <p>SANTA BARBARA, CA – March 30, 2021 – Cancervax, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to treat cancer, today announced it has closed its $2 million series A funding round.</p>

                </div>
            </div>
            <div class="col-lg-6">
                <div class="news-item">
                    <a href="cancervax-launched.php"> </a>
                    <span>March 23, 2021</span>
                    <h3>Cancervax Launched</h3>
                    <p>The Company was founded by experienced healthcare executive Lindsay Mann</p>

                </div>
            </div>
        </div>
    </div>
</section>

<?php
include('footer.php'); ?>